CD47在恶性血液病中的作用  

Role of CD47 in Hematologic Malignancies——Review

作　　者：苏国宏[1] 赵玉磊[1] 

机构地区：[1]沧州市中心医院血液内二科,河北沧州061000

出　　处：《中国实验血液学杂志》2013年第6期1631-1634,共4页Journal of Experimental Hematology

摘　　要：CD47分子是一种广泛表达于多种细胞表面的跨膜糖蛋白,其与整合素配体、信号调节蛋白α(SIRP-α)、凝血酶敏感蛋白(TSP-1)相结合,在炎症反应、免疫应答、肿瘤免疫等方面发挥重要的作用。近年来研究发现,CD47与巨噬细胞表面受体SIRP-α相互作用,传递抑制性调节信号,参与多种恶性血液病的发病,且在临床治疗上具有一定的指导作用。本文就CD47的结构及免疫调节功能、CD47在肿瘤治疗中的机制、CD47与恶性血液病以及CD47与造血干细胞移植进行综述。CD47 is a ubiquitously expressed transmembrane glycoprotein on surface of many cells. Through its interaction with integrin, signal regulatory protein alpha（SIRPα） and thrombin sensitive protein-1 （TSP-1）, it plays important roles in various immunological processes including inflammatory response, immune response and tumor immunity. Recently, it has been found that CD47 interacts with SIRPct expressed on phagocytic cells, which transfers a negative signal when being activated. By the mechanisms described above, CD47-SIRPα signal complex is involved in the pathogenesis of hematological diseases and might provide some informations for the therapy of patients. This review focuses on the structure and immuoregulatory functions of CD47, the mechanism of CD47 in tumor therapy, the CD47 and hematologic malignancies including acute lenkemia, B-cell lymphoma and multiple myeloma, as well as CD47 and hematopoietic stem cell tramspeantation.

关 键 词：CD47 信号调节蛋白 恶性血液病 

分 类 号：R733[医药卫生—肿瘤]